KFF Health Tracking Poll May 2024: The Public’s Use and Views of GLP-1 Drugs

  1. Adults who say a doctor or health care provider told them they are overweight or obese in the past five years include those who may also have diabetes or heart disease.

    ← Return to text

  2. Insufficient sample size to report among uninsured adults who have ever taken these drugs.

    ← Return to text

  3. These drugs are commonly prescribed for weight management, to treat type 2 diabetes, or to reduce the risk of heart attacks and stroke in people with cardiovascular disease. While Medicare is currently prohibited by law from covering medications used specifically for weight loss, Medicare spending on these drugs is currently skyrocketing given their high price and use for diabetes and to reduce cardiovascular risk. For more information, see KFF’s policy watch on rising Medicare spending on Ozempic and other GLP-1 Drugs.

    ← Return to text

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.